• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
URGN

URGN

UroGen Pharma Ltd.

NASDAQHealthcareBiotechnologyUS

USD26.60

+0.06 (+0.23%)

Rating:C

Company Profile

CEO

Elizabeth A. Barrett

IPO Date

2017-05-04

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$26.77

Prev. Close

$26.54

Day Low

$26.26

Day High

$27.24

52W Low

$4.80

52W High

$32.37

Market Cap

$1.30B

Volume

0.48M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

53.7%

Avg Negative

2.6%

Avg Neutral

43.8%

News Feed

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/13/2021·↓ negative

UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments

Business Wire·5/13/2021·↑ positive

UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/18/2021·
↓ negative

UROGEN PHARMA (URGN) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research·3/18/2021·↑ positive

UroGen Pharma: Q4 Earnings Insights

Benzinga·3/18/2021·↑ positive

UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments

Business Wire·3/18/2021·↑ positive

UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline

Business Wire·3/15/2021·↑ positive

Jelmyto And UGN-102 Will Likely Drive Strong Returns For UroGen Shareholders

Seeking Alpha·3/1/2021·↑ positive

URGN Is Worth $50/Share Should It Trade At Revenue Multiples Consistent With Its Peers

Seeking Alpha·1/10/2021·↑ positive

UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference

Business Wire·1/6/2021·↑ positive